Endocrinology News and Research

Latest Endocrinology News and Research

UCF researcher develops first dual vaccine to fight malaria and cholera

A University of Central Florida biomedical researcher has developed what promises to be the first low-cost dual vaccine against malaria and cholera.

27 Jan 2010

Osiris Therapeutics completes enrollment in Prochymal MSC therapy Phase II trial for type 1 diabetes

Osiris Therapeutics, Inc. today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth in a series of payments resulting from JDRF’s partnership with Osiris for the development of a therapy for type 1 diabetes.

27 Jan 2010

Findings may point toward potential therapies for type 2 diabetes

In people who put on a lot of weight, or whose bodies start developing the inability to use insulin effectively that leads toward type 2 diabetes, the pancreas typically ramps up its supply of insulin-generating "beta" cells, at least partly by replication of the existing cells.

27 Jan 2010

Obese children face increased risk of stroke and heart disease

By as early as 7 years of age, being obese may raise a child's risk of future heart disease and stroke, even in the absence of other cardiovascular risk factors such as high blood pressure, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

27 Jan 2010

FDA approves Victoza to treat type 2 diabetes in some adults

The U.S. Food and Drug Administration today approved Victoza (liraglutide), a once-daily injection to treat type 2 diabetes in some adults.

27 Jan 2010

FDA approves Novo Nordisk's Victoza for type 2 diabetes

Novo Nordisk, a global healthcare company, announced today the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza® (liraglutide [rDNA origin] injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.

27 Jan 2010

Number of Americans in excellent or good health has declined

The New York Times reports on health in the U.S. "The percentage of people who reported having excellent or very good health declined to 66.6 percent in the 2009 period, from 69.1 percent in 1998.

27 Jan 2010

Halozyme Therapeutics and BioAtla sign research collaboration agreement

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the signing of an exclusive, worldwide, contract research collaboration agreement with BioAtla, LLC for the development of novel high throughput recombinant protein screening libraries directed against targets in oncology, aesthetic dermatology and inflammation.

25 Jan 2010

Erbitux improves survival of mCRC patients with KRAS wild-type tumors

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Erbitux® (cetuximab) provided an improvement in overall survival (OS) when added to the standard 1st-line FOLFIRI chemotherapy regimen for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors in the CRYSTAL study.

24 Jan 2010

Canadian conference on managing legal & business risks in clinical trials

The nature of clinical trials is constantly changing in the ever-more globalized and adapting market. In this increasingly-scrutinized industry, it is important to maintain a transparent process, to appropriately manage risks and to avoid abuses, in order to get a piece of this multi-billion dollar industry. How? By effectively managing the legal and business risks!

23 Jan 2010

Renowned heart specialists to discuss new cardiovascular treatment and patient care at public forum

World-leading cardiovascular specialists, researchers, family physicians and the public will learn what's new in cardiovascular treatment, patient care and research at the second annual Peter Munk Cardiovascular Symposium, Partnerships in Integrative Patient Care, on January 29 and 30 at the Toronto Metropolitan Hotel.

23 Jan 2010

UK Gill Heart Institute offers individualized fitness program for heart patients

How do you change health habits among a population with some of the highest heart disease rates in the world? Tackling heart disease in Kentucky - an epicenter of heart health problems - the University of Kentucky Gill Heart Institute Cardiac Rehabilitation Program is helping high-risk patients make radical, lasting changes to improve their heart health.

23 Jan 2010

Lifestyle changes are best defense against heart attack

When it comes to heart health, whether or not your job is stressful isn't what you should be worried about, according to doctors at UT Southwestern Medical Center. Diet, exercise and risk factors like high cholesterol, smoking, diabetes, high blood pressure and obesity are what contribute to a person's chance of having a heart attack.

23 Jan 2010

Tips to combat childhood obesity

You've heard the alarming statistic before: one-third of U.S. children and teens are overweight or obese, increasing their risk of developing health problems such as diabetes.

23 Jan 2010

Æterna Zentaris receives notification letter over non-compliance with NASDAQ Listing Rule

Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").

22 Jan 2010

Health Policy Research: Covering young adults, Acos, wellness programs

Dependent Coverage Expansions: Estimating the Impact of Current State Policies - "With an estimated 29.3 percent of Americans age 19 to 29 lacking coverage, young adults are more likely to be uninsured than any other age group," the authors note.

22 Jan 2010

Benefits of DNA testing

Does the term “genetic testing” conjure up thoughts of cloned, robot-like human beings and malevolent plots to rule the world? If so, you’ve been reading too much science fiction! The truth is, DNA testing has been put to very beneficial use for decades, primarily in the medical, law enforcement, and legal fields.

22 Jan 2010

Novo Nordisk on FORTUNE's "100 Best Companies to Work For" list for second consecutive year

Novo Nordisk, a global healthcare company focusing on diabetes care, has been named to FORTUNE Magazine's list of "100 Best Companies to Work For" 2010. This is the second consecutive year that Novo Nordisk has been recognized with this prestigious award. Novo Nordisk moved up to 25 from 57 in the overall list and is only one of two pharmaceutical/biotechnology companies so honored.

From Novo Nordisk 22 Jan 2010

Braille Institute launches Solutions in Sight to help people find fulfillment in different aspects of life

Although there is controversy over almost every detail of health reform legislation, no one disputes the inescapable fact underlying the deepening the health care crisis: the US population is aging.

22 Jan 2010

The American Journal of Pathology: Highlights from February 2010 issue

A group led by Dr. Peter Lloyd Jones at the University of Dundee, Dundee, Scotland; the University of Colorado Denver, Aurora, CO; and the University of Pennsylvania, Philadelphia, PA has demonstrated that tenascin-C affects proto-oncogene function in breast cancer. Their report can be found in the February 2010 issue of The American Journal of Pathology.

22 Jan 2010